CNBC January 9, 2026
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.
Next week, I’ll be attending the annual JPMorgan Healthcare Conference — the largest gathering of biotech and pharma execs, investors and analysts in the U.S.
The conference often sets the tone for the year ahead, and will offer an early pulse on what the health-care industry could look like in 2026. Executives from companies large and small are expected to roll out key business and drug pipeline updates, announce splashy M&A deals and offer their read on industry sentiment more than a year into Trump 2.0.
That backdrop looks different than many...
Today's Sponsors
Today's Sponsor